JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Circulating tumor DNA as a predictive biomarker for treatment response and survival in metastatic colorectal cancer

  • 0Department of Oncology, Maoming People's Hospital, Maoming City, Guangdong Province, China.
International Journal of Colorectal Disease +

|

December 16, 2024

|

December 16, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Circulating tumor DNA (ctDNA) can predict treatment response and survival in metastatic colorectal cancer (mCRC). Negative ctDNA status indicates better outcomes and fewer adverse events, supporting its use in personalized therapy.

Area Of Science

  • Oncology
  • Molecular Diagnostics
  • Cancer Biomarkers

Background

  • Metastatic colorectal cancer (mCRC) presents significant challenges in predicting patient outcomes.
  • Noninvasive biomarkers are crucial for monitoring treatment response and prognosis in mCRC.
  • Circulating tumor DNA (ctDNA) has emerged as a potential tool for molecular profiling in cancer.

Purpose Of The Study

  • To evaluate the prognostic value of circulating tumor DNA (ctDNA) in predicting treatment response and survival in patients with metastatic colorectal cancer (mCRC).
  • To determine if ctDNA status can serve as a noninvasive biomarker for guiding therapeutic strategies in mCRC.

Main Methods

  • Retrospective analysis of 134 mCRC patients treated between January 2020 and December 2021.
  • Classification of patients into ctDNA-negative and ctDNA-positive groups based on plasma ctDNA detection.
  • Analysis of demographic, clinical, laboratory parameters, treatment response, survival outcomes, and adverse events.

Main Results

  • ctDNA-negative patients demonstrated significantly better outcomes than ctDNA-positive patients, including higher objective response rates (65.22% vs. 46.15%) and improved progression-free survival (8.24 months vs. 7.86 months).
  • ctDNA-negative status was associated with superior overall survival (24.58 months vs. 23.27 months) and a higher 1-year survival rate (73.91% vs. 55.38%).
  • The ctDNA-positive group experienced a higher incidence of adverse events, and ctDNA status correlated significantly with tumor markers, treatment response, and survival.

Conclusions

  • Circulating tumor DNA (ctDNA) is a valuable noninvasive biomarker for predicting treatment response, survival outcomes, and adverse events in mCRC patients.
  • ctDNA detection can aid in personalizing therapeutic strategies for metastatic colorectal cancer.
  • Further research into ctDNA dynamics may refine prognostic assessments and treatment decisions in mCRC.

Keywords: